

VIRTUAL EVENT SERIES

DRUG DISCOVERY AND DEVELOPMENT

FEBRUARY 18, 2026



Date	Time	Track	Presentation Title	Speaker
18-Feb	06:00 - 07:00 AM		Accelerate structural studies with novel insights from mass photometry	Brenda Watt, PhD Senior Applications Scientist
18-Feb	07:00 - 08:00 AM	Emerging Modalities in Drug Discovery and Preclinical Development	High-Quality GPCR Antibody Discovery Using Full-Length Nanodisc GPCR Proteins and Single B-Cell Technology	Donghui Ma, PhD CEO, DIMA Biotechnology LTD
18-Feb	07:30 - 08:30 AM	Emerging Modalities in Drug Discovery and Preclinical Development	From Retrosynthesis to Reality: Interactive Pathway Design for Drug Discovery Teams w/ Live Q&A	Dr. Ewa Gajewska, PhD Head of Product Management at at Merck KGaA
18-Feb	09:00 - 10:00 AM	Emerging Modalities in Drug Discovery and Preclinical Development	Keynote Presentation: Drug Development for the Therapy of Mitochondrial Diseases w/ Live Q&A	Volkmar Weissig, ScD, PhD, MS, BS Professor of Pharmacology (tenured) and Biomedical Sciences, Northwestern University
18-Feb	10:30 - 11:30 AM	Improving Drug Discovery & Delivery Methodology	Keynote Presentation: Quo Vadis Personalized Medicine in the early 21st Century? w/ Live Q&A	Dr. Gualberto Ruaño, MD, PhD Principal Investigator Institute of Living at Hartford Hospital
18-Feb	12:00 - 01:00 PM		Unlocking Precision Medicine at Scale: AI-Driven Solutions to Advance BioPharma Development and Commercialization w/ Live Q&A	Jess Lambe, MBA VP & Managing Director BioPharma Business Development, SOPHiA GENETICS
18-Feb	01:30 - 02:30 PM		Possibilities of Loop-mediated Isothermal Amplification	Gintarė Gervaitytė, M.S. Product Manager, Thermo Fisher Scientific
18-Feb	02:30 - 03:30 PM		Keynote Presentation: Translationally Relevant Humanized Mouse Studies: Practical Refinements that Reduce Variability and Improve Reproducibility	Monika Buczek, PhD Director, Humanized Immune Model Core, Taconic Biosciences
18-Feb	03:00 - 04:00 PM		Precision antibody engineering: tailored services for accelerated development	Dr. Rebecca Moschall Staff Scientist, Thermo Fisher Scientific

18-Feb	On Demand	Emerging Modalities in Drug Discovery and Preclinical Development	Accelerating drug discovery of mitochondrial disorders with pluripotent stem cells and brain organoids	Alessandro Prigione, MD, PhD Independent Team Leader, Max Delbrueck Center for Molecular Medicine (MDC)
18-Feb	On Demand	Improving Drug Discovery & Delivery Methodology	From Living Banks to Biomarkers: Integrating PDX and PDO Data Infrastructure for Precision Oncology	Guanqiao Feng, PhD
18-Feb	On Demand	Improving Drug Discovery & Delivery Methodology	The Future of Non-Animal Models: Real Opportunities, Real Constraints, and the Path Forward	Michael Johnson, PhD President, New Jersey Innovation Institute
18-Feb	On Demand	Emerging Modalities in Drug Discovery and Preclinical Development	Unexpected effects of the VEGFR inhibitor cediranib in multiple cancer models	Cai Roberts, PhD Assistant Professor, Pharmacology, Northwestern University - Downers Grove